Most individuals with MDS exhibit gene mutations affecting various gene classes, including epigenetic regulators (e.g., TET2, ASXL1), spliceosome genes (e.g., SF3B1, SRSF2), transcription factors (e.g., TP53, RUNX1), genes associated with signaling pathways (e.g., KRAS, JAK2), and components of the cohesin complex [3]. This evidence concerns the gene TET2 and myelodysplastic syndrome.